Clinical trial NCT04273802: CPX-351 in Higher Risk Myelodysplastic Syndromes
Official title: CPX-351 in Higher Risk Myelodysplastic Syndromes: a Phase I/ II Study as First Line or After Hypomethylating-agents Failure
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Myelodysplastic Syndromes
Keywords: MDS high risk
Lead sponsor: Groupe Francophone des Myelodysplasies
Sponsor class: OTHER
First posted: 2020-02-18
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Cohort A: first line treatment Cohort B: after hypomethylating-agents failure
Primary purpose: TREATMENT

Brief summary: Study of the efficacy of CPX-351 treatment in patients with higher risk myelodysplastic syndromes : as first line treatment or after hypomethylating agents failure

Detailed description: A phase I/II study of the efficacy of CPX-351 treatment in patients with higher risk myelodysplastic syndromes : as first line treatment or after hypomethylating agents failure.

CPX-351 is an advanced liposomal formulation of daunorubicin and cytarabine encapsulated at a 1:5 ratio.

Patients will receive induction treatment with CPX-351. Patients in response (complete response (CR), complete response with incomplete hematologic improvement (CRi), partial response (PR)) after induction will receive monthly courses of consolidation therapy with CPX-351.

Eligibility criteria: Inclusion Criteria:

* Myelodysplastic syndrome (WHO 2016 classified) including CMML (even if white blood cell count (WBC) \> 13000/mm3).
* For COHORT A: untreated patients except by erythropoiesis stimulating agents, Lenalidomide or non-chemotherapy during a phase of lower risk MDS; For COHORT B: absence of response (CR, CRi, PR or HI according to international working group (IWG) 2006 for MDS) after a minimum of 6 cycles of single hypomethylating agent or relapse after a response.
* For COHORT A: less than 20% of marrow blasts. For COHORT B: less than doubling of marrow blasts compared with onset of hypomethylating agent.
* Classical international prognostic scoring system (IPSS) int-2 or high risk score.
* For COHORT A and B : age between 18 and 70 years
* For COHORT A: Performance status (ECOG grading) ≤ 1; For COHORT B: Performance status ≤ 2.
* Eligible for standard intensive chemotherapy.
* Absence of concomitant severe cardiovascular disease which would make intensive chemotherapy impossible, i.e. arrhythmias requiring chronic treatment, congestive heart failure or symptomatic ischemic heart disease, reduced left ventricular function assessed by multigated acquisition (MUGA) scan or echocardiogram.
* Patient must have adequate organ function as indicated by the following laboratory values: Renal: Serum creatinine \< 2 mg/dl or calculated creatinine clearance ≥ 60 mL/min by MDRD (modification of the diet in renal disease) or CKD-EPI (chronic kidney disease epidemiology collaboration) equation for patients with creatinine levels \> 1.5xULN ; Hepatic: Serum total bilirubin ≤ 2.5xULN OR direct bilirubin ≤ ULN for patients with total bilirubin levels ≥ 2 mg/dL, aspartate aminotransferase (ALT) and alanine aminotransferase (ALT) ≤ 2.5xULN, Alkaline Phosphatase ≤ 5xULN (if \> 2.5xULN, then liver fraction should be ≤ 2.5xULN).
* Patients not known to be refractory to platelet transfusions.
* Female subjects of child-bearing potential must agree to undergo medically supervised pregnancy test prior to starting study drug. The first pregnancy test will be performed at screening (within 7 days prior to first study drug administration), and on the day of the first study drug administration and confirmed negative prior to dosing and Day 1 before dosing all subsequent cycles. Female patient is not actively breastfeeding at the time of study entry.
* Female patients are either post-menopausal, free from menses for \> 2 years, surgically sterilized or willing to use 2 adequate barrier methods of contraception to prevent pregnancy or agree to abstain from becoming pregnant throughout the study, starting with Visit 1. Females of reproductive potential as well as fertile men and their partners who are female of reproductive potential must agree to abstain from sexual intercourse or to use two highly effective forms of contraception from the time of giving informed consent, during the study and for 6 months (females and males) following the last dose of CPX-351.
* Male patients agree to use an adequate method of contraception for the duration of the study. Men should be advised not to father a child while receiving CPX-351 and for 6 months post study.
* Patients are available for regular blood sampling, study related assessments, and appropriate clinical management at the treating institution for the duration of the study.
* Patients have the ability to understand and willingness to sign an informed consent form indicating the investigational nature of the study.

Exclusion Criteria:

* Active and uncontrolled infection.
* Last dose of hypomethylating agent given more than 4 months before entering the trial.
* Uncontrolled intercurrent illness or circumstances that could limit compliance with the study, including but not limited to the following: symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, pancreatitis, or psychiatric or social conditions that may interfere with patient compliance.
* Current participation or participation in a study with an investigational compound or device within 30 days of initial dosing with study drug.
* Known human immunodeficiency virus (HIV) infection or HIV-related malignancy.
* Clinically active hepatitis B or hepatitis C infection.
* Known allergy or hypersensitivity to any component of CPX-351.
* "Currently active" second malignancy, other than non-melanoma skin cancer and in situ carcinoma of the cervix.
* Subjects with a history of Wilson's disease or other copper-related disorder.
* Treatment with growth factors such as erythropoietin alfa (EPO) or granulocyte colony-stimulating factor (G-CSF) or cytotoxic and non-cytotoxic agents (including low dose oral chemotherapy with the exception of hydroxyurea) in the 30 days before inclusion.
* Treatment with systemic steroids that has not been stabilized to the equivalent of ≤ 10 mg/day prednisone during the 4 weeks prior to the start of the study drugs.
* Clinical evidence of central nervous system leukemia.
* Pregnancy or breastfeeding during the projected duration of the study.
* Absence of social security.

Primary outcomes:
measure: Response rate (CR, CRi, PR)
timeFrame: 28 to 42 days after induction
Secondary outcomes:
measure: Overall response rate (CR, CRi, PR, HI)
timeFrame: 28 to 42 days after induction
measure: Event free survival
timeFrame: 42 months
measure: Response duration
timeFrame: 42 months
measure: Overall survival
timeFrame: 42 months
measure: Toxicity profile - Duration of cytopenias
timeFrame: 42 months
measure: Toxicity profile - life threatening or fatal cytopenias
timeFrame: 42 months
measure: Toxicity profile - hospitalization
timeFrame: 42 months
measure: Evaluation of minimal residual disease (MRD) after induction and after the last consolidation
timeFrame: 42 months
measure: Evaluation of minimal residual disease (MRD) after induction and after the last consolidation
timeFrame: 42 months
measure: Soluble Fms-like tyrosine kinase 3 ligand concentration (sFLc) in plasma during induction
timeFrame: 42 months
Other outcomes:
Locations:
city: Amiens
country: France
facility: CHU d'Amiens - Service d'hématologie clinique et thérapie cellulaire
city: Angers
country: France
facility: CHU d'Angers - Service des maladies du sang
city: Argenteuil
country: France
facility: Centre hospitalier Victor Dupouy - Service d'Hématologie
city: Besançon
country: France
facility: CHU de Besançon - Hôpital Jean Minjoz - Service d'hématologie clinique
city: Grenoble
country: France
facility: CHU de Grenoble - Clinique universitaire d'hématologie
city: Le Mans
country: France
facility: CH Le Mans - Service d'onco-hématologie
city: Limoges
country: France
facility: CHRU de Limoges - Hôpital Dupuytren - Service d'hématologie clinique et thérapie cellulaire
city: Marseille
country: France
facility: Institut Paoli Calmettes - Unité d'hématologie 3
city: Nantes
country: France
facility: CHU Hôtel Dieu - Service d'Hématologie Clinique
city: Nice
country: France
facility: CHU-Hôpital Archet I - Service d'Hématologie Clinique
city: Paris
country: France
facility: Hôpital Saint Louis - Service Hématologie Séniors
city: Pessac
country: France
facility: CHU de Bordeaux - Hôpital de Haut-Lévêque - Service des maladies du sang
city: Poitiers
country: France
facility: CHU de Poitiers - Service d'onco-hématologie et thérapie cellulaire
city: Rennes
country: France
facility: Hôpital Pontchaillou - Service d'hématologie clinique
city: Saint Priest-en-Jarez
country: France
facility: Institut de Cancérologie Lucien Neuwirth - Hématologie Clinique - Thérapie Cellulaire
city: Toulouse
country: France
facility: IUCT-oncopole - Fédération Hématologie - Médecine Interne
Study officials:
affiliation: Nantes University Hospital
name: Pierre PETERLIN, MD
role: PRINCIPAL_INVESTIGATOR
References: